Compare Crispr Therapeutics AG (CRSP) vs Corsair Gaming Inc (CRSR) Price & Performance

CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.

The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.

Corsair Gaming (CRSR) trades at $13.09, down 3.68% today but showing strong earnings momentum with three consecutive quarterly beats. The stock maintains a bullish technical signal with current price near pivot point support at $13. Recent Q2 2026 results exceeded expectations with EPS of $0.23 versus $0.07 estimate, driving positive sentiment from institutional investors including Canada Pension Plan's new position. The company continues product innovation with VOXARA microphone launch and strategic acquisitions like Trak Racer assets.

While valuation appears elevated with P/E of 42.23, improving profitability trends and raised 2026 guidance support upside potential. Key risks include competitive gaming peripherals market and inconsistent cash flow generation. Analyst consensus shows mixed sentiment with 36% buy ratings but average price target of $12.40 suggests limited near-term upside from current levels.